<a href="https://www.fiercebiotech.com/biotech/city-lay-foundation-rnai-renaissance-nearly-100m-series-b" hreflang="en">City aims to lay foundation for RNAi renaissance with nearly $100M series B</a>
City Therapeutics has secured nearly $100 million in Series B funding to advance its RNA interference (RNAi) therapies, aiming to innovate beyond liver-targeted treatments into new tissue types. The company plans to develop its lead candidate targeting Factor XI, which could benefit patients unable to use existing anticoagulants, while also seeking partnerships to enhance its platform and clinical development.
City Therapeutics is strategically positioning itself to lead the next wave of RNA interference (RNAi) innovation by raising nearly $100 million in series B funding, with plans to focus on extra-hepatic delivery systems, an area where less than 5% of current clinical programs are active. This represents a significant opportunity for innovation and market leadership in RNAi therapeutics, especially as they develop partnerships to extend their platform capabilities and advance clinical candidates like the Factor XI program, which targets patients unsuitable for current anticoagulant therapies.